Drug Trial Radar · NCT07800897
A Study of Navlimetostat (BMS-986504) Drug Interactions and Food Effect in Healthy Participants
Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Aug 31, 2026
Primary completion
Mar 25, 2027
Study completion Mar 25, 2027
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Sep 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the food effect and drug interactions on drug levels of Navlimetostat in health adult female participants
Conditions
- Healthy Female Adults
Interventions
NavlimetostatDrug
Specified dose on specified days
ItraconazoleDrug
Specified dose on specified days
RifampinDrug
Specified dose on specified days
MidazolamDrug
Specified dose on specified days
PantoprazoleDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed concentration (Cmax) of NavlimetostatTime frame: Up to approximately 3 weeks
- Area under the concentration-time curve from time zero to 192 hours (AUC(0-192)) of NavlimetostatTime frame: Up to approximately 3 weeks
- (AUC(INF)) of Navlimetostat with the coadministration of itraconazoleTime frame: Up to approximately 3 weeks
- AUC(INF) of Navlimetostat without the coadministration of itraconazoleTime frame: Up to approximately 3 weeks
- Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) of NavlimetostatTime frame: Up to approximately 3 weeks
- AUC(INF) of Navlimetostat with the coadministration of RifampinTime frame: Up to approximately 3 weeks
- AUC(INF) of Navlimetostat without the coadministration of RifampinTime frame: Up to approximately 3 weeks
- Cmax of MidazolamTime frame: Up to approximately 3 weeks
- AUC(0-T) of MidazolamTime frame: Up to approximately 3 weeks
- AUC(INF) of Midazolam with the coadministration of NavlimetostatTime frame: Up to approximately 3 weeks
- AUC(INF) of Midazolam without the coadministration of NavlimetostatTime frame: Up to approximately 3 weeks
- AUC(INF) of Navlimetostat with a high fat mealTime frame: Up to approximately 3 weeks
- AUC(INF) of Navlimetostat without a high fat mealTime frame: Up to approximately 3 weeks
- AUC(INF) of Navlimetostat with the coadministration of PantoprazoleTime frame: Up to approximately 3 weeks
- AUC(INF) of Navlimetostat without the coadministration of PantoprazoleTime frame: Up to approximately 3 weeks
- Drug-related AEsTime frame: Up to approximately 6 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Syneos Health Clinique; Inc.
Québec, Quebec, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.